Skip to main content
Oxford Research Peptides
RESEARCH PRIMER

What is Tirzepatide?

A concise, evidence-based introduction to Tirzepatide — a dual GIP / GLP-1 receptor agonist positioned between Semaglutide (mono-agonist) and Retatrutide (triple agonist) in incretin pharmacology.

QUICK ANSWER
TL;DR

Quick answer

Tirzepatide is a synthetic 39-residue peptide that simultaneously activates the GIP receptor and the GLP-1 receptor — the first dual incretin receptor agonist to reach clinical use. Its GIP-based backbone carries Aib substitutions at positions 2 and 13 for DPP-4 resistance and a C20 fatty-di-acid at lysine 20 for reversible albumin binding, together supporting a plasma half-life of about five days and once-weekly subcutaneous dosing.
EXTENDED ANSWER
AI-ready

Extended answer

What is Tirzepatide?

Tirzepatide is a synthetic 39-residue linear peptide first characterised in the peer-reviewed literature by Coskun and colleagues in 2018 as the novel dual GIP and GLP-1 receptor agonist LY3298176. Its backbone is derived from GIP rather than GLP-1 and carries α-aminoisobutyric acid substitutions at positions 2 and 13 to resist DPP-4 cleavage, together with a C20 fatty-di-acid at lysine 20 attached through a γGlu-2xOEG spacer that supports reversible binding to serum albumin. These changes give a plasma half-life of approximately five days and enable once-weekly subcutaneous dosing. Tirzepatide is the first approved dual incretin receptor agonist and sits between GLP-1 mono-agonists such as Semaglutide and triple GLP-1 / GIP / glucagon agonists such as Retatrutide. Oxford Research Peptides supplies Tirzepatide as a lyophilised reference standard for in-vitro laboratory research only.
KEY FACTS

Key facts

Compound
Tirzepatide
Targets
GIPR + GLP-1R (dual agonist)
Class
Dual incretin receptor agonist
Half-life
≈ 5 days (human, subcutaneous)

Definition and origin

Tirzepatide (development code LY3298176) is a synthetic peptide first described by Coskun and colleagues in 2018 as a novel dual agonist of the GIP and GLP-1 receptors.[1] It was designed to combine the physiological actions of both incretin hormones in a single molecule with once-weekly kinetics.

Why dual agonism?

Native GIP and native GLP-1 act at different receptors on overlapping but non-identical cell populations. Combining agonism at both receptors was hypothesised to broaden the incretin response — engaging additional GIP-responsive tissues (particularly adipose) alongside GLP-1R signalling in β-cells, α-cells and appetite-regulating central circuits.[9][8]

Relationship to Semaglutide

Semaglutide is a mono-agonist selective for the GLP-1 receptor. Tirzepatide activates the GLP-1 receptor as well, but reported in-vitro pharmacology characterises its GLP-1R engagement as biased: it recruits less β-arrestin than native GLP-1 at matched G-protein signalling, and the second receptor arm (GIPR) adds pharmacology that Semaglutide does not have.[2] The SURPASS-2 head-to-head trial compared once-weekly Tirzepatide with once-weekly Semaglutide in type 2 diabetes.[4]

Relationship to Retatrutide

Retatrutide is a triple agonist that adds a third arm — the glucagon receptor — to the GLP-1 / GIP dual mechanism. Tirzepatide does not appreciably engage the glucagon receptor, so the design goals differ: Tirzepatide targets incretin-axis potentiation, while Retatrutide additionally modulates energy expenditure through hepatic and adipocyte glucagon-receptor signalling.

Research context

Tirzepatide has been evaluated in the SURPASS programme for type 2 diabetes (SURPASS-1 monotherapy vs placebo,[3] SURPASS-2 vs Semaglutide[4]) and in the SURMOUNT programme for weight management (SURMOUNT-1 in adults with obesity).[5]

Research-use framing

Approved Tirzepatide medicines are prescription therapeutics regulated by the MHRA in the United Kingdom. Oxford Research Peptides supplies Tirzepatide strictly as a lyophilised reference standard for in-vitro laboratory research. See Research Use Only and Testing & Quality Control.

Related reading: Tirzepatide monograph, What is Tirzepatide, Tirzepatide mechanism of action, Semaglutide monograph, Retatrutide monograph, GLP-1 receptor explained, Triple agonists explained, Albumin binding, Incretin effect, Research Use Only and Testing & Quality Control.

References9

  1. 1.

    Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept.. Molecular Metabolism. 2018;18:3-14.

    DOI: 10.1016/j.molmet.2018.09.009PMID: 30293807
  2. 2.

    Willard FS, Douros JD, Gabe MBN, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.. JCI Insight. 2020;5(17):e140532.

    DOI: 10.1172/jci.insight.140532PMID: 32730231
  3. 3.

    Rosenstock J, Wysham C, Frías JP, et al.. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1).. The Lancet. 2021;398(10295):143-155.

    DOI: 10.1016/S0140-6736(21)01324-6PMID: 34186022
  4. 4.

    Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).. New England Journal of Medicine. 2021;385(6):503-515.

    DOI: 10.1056/NEJMoa2107519PMID: 34170647
  5. 5.

    Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).. New England Journal of Medicine. 2022;387(3):205-216.

    DOI: 10.1056/NEJMoa2206038PMID: 35658024
  6. 6.

    Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.. Gastroenterology. 2007;132(6):2131-2157.

    DOI: 10.1053/j.gastro.2007.03.054PMID: 17498508
  7. 7.

    Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.. Cell Metabolism. 2018;27(4):740-756.

    DOI: 10.1016/j.cmet.2018.03.001PMID: 29617641
  8. 8.

    Nauck MA, Meier JJ. GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family.. Diabetes. 2021;70(9):1955-1966.

    DOI: 10.2337/dbi21-0003PMID: 34417262
  9. 9.

    Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1?. Trends in Endocrinology & Metabolism. 2020;31(6):410-421.

    DOI: 10.1016/j.tem.2020.02.006PMID: 32396843
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
Tirzepatide's identity, structure and dual-receptor selectivity are established in peer-reviewed pharmacology. Its efficacy has been evaluated in large randomised clinical trials in type 2 diabetes (SURPASS) and obesity (SURMOUNT), including head-to-head comparison with Semaglutide.
RELATED GUIDES
COMPOUND REFERENCE
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-11-05
Updated
2026-11-05
Reviewed
2026-11-05
Version
1.0

Revision history

  1. v1.02026-11-05· Editorial Team

    Initial publication of the Tirzepatide cornerstone cluster (Authority Sprint 3B).

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-05-05. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-11-05Updated: 2026-11-05